Login to Your Account



PharmaFocus

Temporary Win for Copaxone; Bigger Threats in MS Pipeline

By Jennifer Boggs
Managing Editor

Tuesday, June 26, 2012
With a district court judge ruling in favor of Teva Pharmaceutical Industries Ltd.'s patent infringement lawsuit, the Jerusalem-based big pharma should be able to prevent generic competition to its multiple sclerosis (MS) drug Copaxone (glatiramer acetate) from hitting the market until at least Sept. 1, 2015.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription